<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2315">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05131022</url>
  </required_header>
  <id_info>
    <org_study_id>NX-5948-301</org_study_id>
    <nct_id>NCT05131022</nct_id>
  </id_info>
  <brief_title>A Phase 1 Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies</brief_title>
  <official_title>A Phase 1, Dose Escalation, and Cohort Expansion Study Evaluating NX-5948, a Bruton's Tyrosine Kinase (BTK) Degrader, in Adults With Relapsed/Refractory B-cell Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nurix Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nurix Therapeutics, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a first-in-human dose escalation and cohort expansion multicenter, open-label study&#xD;
      designed to evaluate the safety and preliminary efficacy of NX-5948 in patients with advanced&#xD;
      B-cell malignancies.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There are 2 parts to this study. The phase 1a portion (dose escalation) evaluates the safety&#xD;
      and tolerability of NX-5948 in adult patients with relapsed/refractory (R/R) chronic&#xD;
      lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), diffuse large B-cell lymphoma&#xD;
      (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL),&#xD;
      or Waldenströms macroglobulinemia (WM), who have received at least 2 prior systemic therapies&#xD;
      (1 prior therapy for WM), and for whom no other therapies are known to provide clinical&#xD;
      benefit.&#xD;
&#xD;
      The phase 1b portion (cohort expansion) investigates the efficacy of NX-5948 at the dose&#xD;
      selected in Phase 1a in up to 5 cohorts of patients with R/R B-cell malignancies, who have&#xD;
      received at least 2 prior systemic therapies (or 1 prior therapy for patients with WM,&#xD;
      primary central nervous system lymphoma (PCNSL), or secondary central nervous system&#xD;
      involvement.&#xD;
&#xD;
        -  Cohort A: CLL or (SLL) without a BTK C481 mutation&#xD;
&#xD;
        -  Cohort B: CLL or SLL with a BTK C481 mutation&#xD;
&#xD;
        -  Cohort C: DLBCL or MCL&#xD;
&#xD;
        -  Cohort D: FL, MZL, or WM&#xD;
&#xD;
        -  Cohort E: PCNSL, or any of the indications listed above with Central Nervous System&#xD;
           involvement&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">May 2024</completion_date>
  <primary_completion_date type="Anticipated">January 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with protocol specified dose-limiting toxicities</measure>
    <time_frame>Up to 10 months</time_frame>
    <description>Phase 1a</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To establish the maximum tolerated dose and/or recommended Phase 1b dose</measure>
    <time_frame>Up to 10 months</time_frame>
    <description>Phase 1a</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate the anti-tumor activity of NX-5948 at the recommended Phase 1b dose based on overall response rate (ORR) as assessed by the Investigator</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Phase 1b</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with treatment-emergent adverse events (TEAEs); Grade 3, 4, 5 TEAEs, serious adverse events (SAEs), TEAEs leading to study drug discontinuation, deaths due to TEAEs, and all deaths</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Phase 1a/1b</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) profile of NX-5948: Maximum Serum Concentration</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Phase 1a/1b - Sampling following the first dose, pre- and post-dose at selected cycles and at the end of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic (PD) profile of NX-5948: Changes from baseline of BTK levels in B-cells</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Phase 1a/1b - Sampling at screening, following the first dose, pre and post-dose at selected cycles and at the end of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete response (CR) rate / CR with incomplete marrow recovery as assessed by the Investigator</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Phase 1a/1b</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR) as assessed by the Investigator</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Phase 1a/1b</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS) as assessed by the Investigator</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Phase 1a/1b</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to next therapy</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Phase 1a/1b</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Chronic Lymphocytic Leukemia (CLL)</condition>
  <condition>Small Lymphocytic Lymphoma (SLL)</condition>
  <condition>Diffuse Large B Cell Lymphoma (DLBCL)</condition>
  <condition>Follicular Lymphoma (FL)</condition>
  <condition>Mantle Cell Lymphoma (MCL)</condition>
  <condition>Marginal Zone Lymphoma (MZL)</condition>
  <condition>Waldenstrom Macroglobulinemia (WM)</condition>
  <condition>Primary Central Nervous System Lymphoma (PCNSL)</condition>
  <arm_group>
    <arm_group_label>Phase 1a Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple dose levels of NX-5948 to be evaluated; determination of Maximum Tolerated Dose/Phase 1b recommended dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1b Cohort Expansion in CLL or SLL without a BTK C481 mutation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CLL or SLL without a BTK C481 mutation with disease progression on a BTK inhibitor (BTKi)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1b Cohort Expansion in CLL or SLL with a BTK C481 mutation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CLL or SLL with a BTK C481 mutation with disease progression on a BTKi</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1b Cohort Expansion in DLBCL or MCL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DLBCL with disease progression on an anthracycline and an anti-CD20 monoclonal antibody (mAb)-based regimen, or MCL with disease progression on a BTKi and an anti-CD20 mAb-based regimen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1b Cohort Expansion in FL, MZL, or WM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FL with disease progression on an anti-CD20 mAb-based regimen, MZL with disease progression on an anti-CD20 mAb-based regimen, or WM with disease progression on a BTKi</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1b Cohort Expansion in PCNSL or secondary CNS involvement</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PCNSL with disease progression on 1 prior therapy, or any of the indications listed above with CNS involvement, with disease progression on 1 prior therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NX-5948</intervention_name>
    <description>Oral NX-5948</description>
    <arm_group_label>Phase 1a Dose Escalation</arm_group_label>
    <arm_group_label>Phase 1b Cohort Expansion in CLL or SLL with a BTK C481 mutation</arm_group_label>
    <arm_group_label>Phase 1b Cohort Expansion in CLL or SLL without a BTK C481 mutation</arm_group_label>
    <arm_group_label>Phase 1b Cohort Expansion in DLBCL or MCL</arm_group_label>
    <arm_group_label>Phase 1b Cohort Expansion in FL, MZL, or WM</arm_group_label>
    <arm_group_label>Phase 1b Cohort Expansion in PCNSL or secondary CNS involvement</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must be ≥18 years of age.&#xD;
&#xD;
          -  Patients in Phase 1a (Dose Escalation) must have histologically confirmed R/R CLL,&#xD;
             SLL, DLBCL, FL, MCL, MZL, or WM.&#xD;
&#xD;
          -  Patients in Phase 1a must meet the following:&#xD;
&#xD;
             o Received at least 2 prior systemic therapies (1 prior therapy for WM) and have no&#xD;
             other therapies known to provide clinical benefit.&#xD;
&#xD;
          -  Patients in Phase 1b (Cohort Expansion) must have histologically confirmed R/R CLL,&#xD;
             SLL, DLBCL, FL, MCL, MZL, WM, PCNSL or any of the above indications with CNS&#xD;
             involvement&#xD;
&#xD;
          -  Patients in Phase 1b (Cohort Expansion) must meet criteria for systemic treatment and&#xD;
             must have failed 2 prior lines of therapy (or 1 prior line of therapy for patients&#xD;
             with WM, PCNSL, or secondary CNS involvement).&#xD;
&#xD;
          -  Patients must have radiographically measurable disease per response criteria specific&#xD;
             to the malignancy, evaluable disease in bone marrow or other compartments is also&#xD;
             allowed.&#xD;
&#xD;
          -  ECOG performance status of 0 or 1.&#xD;
&#xD;
          -  Adequate organ and bone marrow function, in the absence of growth factors and without&#xD;
             platelet transfusions as defined by lab parameters&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Prior treatment for the indication under study including:&#xD;
&#xD;
               1. Radiotherapy within 2 weeks of planned start of study drug (excluding limited&#xD;
                  palliative radiation).&#xD;
&#xD;
               2. Prior chemotherapy within 4 weeks of planned start of study drug.&#xD;
&#xD;
               3. Prior monoclonal antibody therapy within 4 weeks of planned start of study drug.&#xD;
&#xD;
               4. Prior small molecule therapy within 4 weeks or 5 half-lives (whichever is&#xD;
                  shorter) of planned start of study drug.&#xD;
&#xD;
               5. Autologous or allogeneic stem cell transplant within 100 days prior to planned&#xD;
                  start of study drug.&#xD;
&#xD;
               6. Chimeric antigen receptor T-cell (CAR-T) therapy within 100 days prior to start&#xD;
                  of study drug (30 days for Phase 1b). Must have evidence of B-cell recovery if&#xD;
                  patient received prior CAR-T therapy.&#xD;
&#xD;
               7. Use of systemic corticosteroids within 14 days prior to first dose of study drug&#xD;
                  of &gt;20 mg/day prednisone or &gt; 4 mg/day of dexamethasone or equivalent for&#xD;
                  patients without CNS lymphoma (CNSL), or &gt;40 mg/day prednisone or &gt;8 mg/day&#xD;
                  dexamethasone or equivalent for patients with CNSL, except for prophylaxis for&#xD;
                  radio diagnostic contrast reactions. Patients with CNSL using &gt;20 mg/day&#xD;
                  prednisone or &gt;4 mg/day dexamethasone or equivalent must be clinically stable at&#xD;
                  that dose for 14 days.&#xD;
&#xD;
               8. Use of immunosuppressive drugs other than systemic corticosteroids within 30 days&#xD;
                  prior to first dose of study drug&#xD;
&#xD;
          -  Active, uncontrolled autoimmune hemolytic anemia or autoimmune thrombocytopenia.&#xD;
&#xD;
          -  Patient has any of the following:&#xD;
&#xD;
               1. Myocardial infarction, unstable angina, unstable symptomatic ischemic heart&#xD;
                  disease, or placement of a coronary arterial stent within 6 months of planned&#xD;
                  start of study drug.&#xD;
&#xD;
               2. Uncontrolled atrial fibrillation or other clinically significant arrhythmias,&#xD;
                  conduction abnormalities, or New York Heart Association (NYHA) class III or IV&#xD;
                  heart failure within 6 months of planned start of study drug.&#xD;
&#xD;
               3. Thromboembolic events (e.g., deep vein thrombosis, pulmonary embolism, or&#xD;
                  symptomatic cerebrovascular events), stroke, or intracranial hemorrhage within 6&#xD;
                  months of planned start of study drug.&#xD;
&#xD;
               4. Any other significant cardiac condition (e.g., pericardial effusion, restrictive&#xD;
                  cardiomyopathy, severe untreated valvular stenosis, severe congenital heart&#xD;
                  disease, or persistent uncontrolled hypertension defined as systolic blood&#xD;
                  pressure &gt; 160 mmHg or diastolic blood pressure &gt; 100 mmHg despite optimal&#xD;
                  medical management) within 6 months of planned start of study drug.&#xD;
&#xD;
          -  Bleeding diathesis, or other known risk for acute blood loss.&#xD;
&#xD;
          -  History of Grade ≥ 2 hemorrhage within 28 days.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Su Young Kim, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Nurix Therapeutics, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Patient Outreach</last_name>
    <phone>(415) 230-7860</phone>
    <email>NX5948301@nurixtx.com</email>
  </overall_contact>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 12, 2021</study_first_submitted>
  <study_first_submitted_qc>November 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 23, 2021</study_first_posted>
  <last_update_submitted>November 12, 2021</last_update_submitted>
  <last_update_submitted_qc>November 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>BTK Degrader</keyword>
  <keyword>BTK Inhibitor</keyword>
  <keyword>B-Cell Malignancy</keyword>
  <keyword>Lymphoma</keyword>
  <keyword>C481</keyword>
  <keyword>C481S</keyword>
  <keyword>Bruton's Tyrosine Kinase</keyword>
  <keyword>NX-5948</keyword>
  <keyword>Targeted Protein Degradation</keyword>
  <keyword>Chimeric Targeting Molecule (CTM)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
    <mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

